Advm nasdaq.

Find the latest SEC Filings data for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com. Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the ...Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness.ADVM Earnings Date and Information. Adverum Biotechnologies last posted its quarterly earnings results on August 10th, 2023. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.01. Adverum Biotechnologies has generated ($1.33) earnings per share …

Mar 29, 2022 · Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy ... ADVM NASDAQ. ADVM NASDAQ. ADVM NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 3.80 0.00 0.00%. The 5 analysts offering 1 year price forecasts for ADVM have a max estimate of — and a min estimate of —. Analyst rating.Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar

Adverum Biotechnologies, Inc. Common Stock (ADVM) Nasdaq Listed. CLOSED AT 4:00 PM ET ON May 26, 2022. DATA AS OF May 26, 2022 6:45 PM ET - AFTER HOURS. 0. No Notifications. Add to Watchlist.

ADVM Stock Overview Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. …Analyst Price Forecast Suggests 375.02% Upside. As of November 1, 2023, the average one-year price target for Adverum Biotechnologies is 4.34. The forecasts range from a low of 3.03 to a high of ...Adverum Biotechnologies grew its revenue by 2,900% over the last year. That's well above most other pre-profit companies. So the hefty 81% share price crash makes us think the company has somehow ...ADVM Adverum Biotechnologies Inc Statement of Ownership (sc 13g) UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ...

Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. If an investor was to purchase shares of ADVM stock at the current price ...

Apr 7, 2022 2:50PM EDT. Adverum Biotechnologies, Inc. ADVM announced that it has received feedback from the FDA on its investigational new drug (IND) application for initiating a phase II study to ...

Average portfolio weight of all funds dedicated to ADVM is 0.15%, an increase of 27.12%. Total shares owned by institutions decreased in the last three months by 2.62% to 57,936K shares.Find the latest Revenue & EPS data for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com.Based on analysts offering 12 month price targets for ADVM in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of ...Mar 1, 2021 · Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of ...

(NASDAQ: ADVM) Adverum Biotechnologies currently has 100,993,010 outstanding shares. With Adverum Biotechnologies stock trading at $0.91 per share, the total value of Adverum Biotechnologies stock (market capitalization) is $91.90M.Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) – Research analysts at Chardan Capital increased their FY2023 earnings estimates for shares of Adverum Biotechnologies in a research note issued to investors on Monday, November 13th. Chardan Capital analyst D. Gataulin now expects that the biotechnology company …2022 оны 9-р сарын 30 ... 30, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a ...Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: -0.4% Health-care shares were mainly unchanged in pre-market trade on Friday..After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain. Key Insights Given the large stake in the stock by ... Advantage Solutions Inc. Class A Common Stock (ADV) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

View real-time ADVM stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

As of February 8, 2023, the average one-year price target for Adverum Biotechnologies is $3.74. The forecasts range from a low of $2.02 to a high of $6.30. The average price target represents an ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Back to ADVM Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Find the latest Insider Activity data for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com.Adverum Biotechnologies Inc (NASDAQ:ADVM) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held ...Average portfolio weight of all funds dedicated to ADVM is 0.15%, an increase of 27.12%. Total shares owned by institutions decreased in the last three months by 2.62% to 57,936K shares.

Find the latest dividend history for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com.

Find the latest Revenue & EPS data for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com.

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy ...NASDAQ: ADVM Adverum Biotechnologies, Inc. Market Cap. $82M. Today's Change (-0.82%) -$0.01 ... ADVM-022 is an experimental gene therapy for the treatment of diabetic macular edema (DME). After ...Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. If an investor was to purchase shares of ADVM stock at the current price ...About Adverum Biotechnologies Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is ...Overview Stock Screener Earnings Calendar Sectors Nasdaq | ADVM U.S.: Nasdaq Adverum Biotechnologies Inc. Watch Set a price target alert After Hours Last Updated: …Jan 15, 2021 · Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. If an investor was to purchase shares of ADVM stock at the current price ... Dec 1, 2023 · Market Capitalization. $81.70 million. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $3.50. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media Sustainability. ADVM NASDAQ. ADVM NASDAQ. ADVM NASDAQ. Mercado fechado Mercado fechado. Sem negociações. Veja nos super gráficos. Visão geral . Notícias Ideias Finanças Sinais …Adverum Biotechnologies, Inc. Common Stock (ADVM) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Jul 22, 2021 · Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy ... ADVM Growth Metrics. Its 2 year cash and equivalents growth rate is now at -29.74%. Its year over year price growth rate is now at -75.37%. The 2 year price growth rate now stands at -95.53%. ADVM's revenue has moved down $2,003,000 over the prior 49 months. The table below shows ADVM's growth in key financial areas (numbers in millions of US ...

Nasdaq: ABEO: 4: Adverum Biotechnologies: Adverum is a clinical-stage gene therapy company focused on ocular and rare diseases. ADVM-022: Nasdaq: ADVM: 5: Alnylam: Founded in 2002, Alnylam has played a leading role in the translation of RNA interference (RNAi) into novel medicines. The company has scored approvals for several …Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum …Find the latest Revenue & EPS data for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com.According to the issued ratings of 4 analysts in the last year, the consensus rating for Adverum Biotechnologies stock is Buy based on the current 4 buy ratings for ADVM. The average twelve-month price prediction for Adverum Biotechnologies is $3.50 with a high price target of $6.00 and a low price target of $2.00.Instagram:https://instagram. apamanhow much is a susan b anthony 1979 worthspy ex dividend datessell broken iphones near me 2023 оны 11-р сарын 6 ... (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases ... gates corphealixa May 1, 2021 · Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of ... May 18, 2023 · Adverum BiotechnologiesAdverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with ... how much are kennedy half dollars worth Complete Adverum Biotechnologies Inc. stock information by Barron's. View real-time ADVM stock price and news, along with industry-best analysis.Jul 6, 2022 · Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the ... 2,837,689. 1.242504. Back to ADVM Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and ...